A 77-year-old woman was treated with ipilimumab and nivolumab for stage 4 melanoma. Five months after treatment initiation, she developed severe generalized weakness. Lab test results revealed low free T4 of 0.7 ng/dL (0.9-1.7 ng/dL) and an inappropriately normal thyroid-stimulating hormone (TSH) of 0.62 μIU/ mL (0.50-5.00 μIU/mL). Brain magnetic resonance imaging (MRI) for evaluation of central hypothyroidism showed diffuse pituitary enlargement and stalk thickening, consistent with hypophysitis (Figs. 1B, D 
CASE
A 77-year-old woman was treated with ipilimumab and nivolumab for stage 4 melanoma. Five months after treatment initiation, she developed severe generalized weakness. Lab test results revealed low free T4 of 0.7 ng/dL (0.9-1.7 ng/dL) and an inappropriately normal thyroid-stimulating hormone (TSH) of 0.62 μIU/ mL (0.50-5.00 μIU/mL). 
